Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression): Version 4.2
- PMID: 39999260
- Bookshelf ID: NBK612354
- DOI: 10.17917/PJNB-JJ95
Leukocyte Proliferation Assay (Immunostimulation and Immunosuppression): Version 4.2
Excerpt
This document describes a protocol for assessing the effect of a nanoparticle formulation on the basic immunologic function of human lymphocytes, i.e. measurement of lymphocyte proliferative responses [1, 2]. This assay will allow for measurement of a nanoparticles’ ability to induce proliferative response of human lymphocytes (part A) or to suppress that induced by phytohemaglutinin (PHA-M) (part B). Parts A and B can typically be run concurrently on the same test plate. Part A is also available as a separate protocol entitled ITA-6.2. Part B is available as a separate protocol with a modification to allow for 24 hr exposure to nanoparticle prior to challenge with PHA-M, and is entitled ITA-6.3.
Sections
Similar articles
-
Leukocyte Proliferation Assay (Immunosuppression): Version 2.1.2024 Jul. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.3. 2024 Jul. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.3. PMID: 40198039 Free Books & Documents. Review.
-
Leukocyte Proliferation Assay: Version 2.2020 May. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.3. 2020 May. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.3. PMID: 39013061 Free Books & Documents. Review.
-
Leukocyte Proliferation Assay (Immunostimulation): Version 2.1.2024 Jul. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.2. 2024 Jul. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.2. PMID: 40198038 Free Books & Documents. Review.
-
Leukocyte Proliferation Assay: Version 2.2020 May. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.2. 2020 May. In: National Cancer Institute’s Nanotechnology Characterization Laboratory Assay Cascade Protocols [Internet]. Bethesda (MD): National Cancer Institute (US); 2005 May 1–. NCL Method ITA-6.2. PMID: 39013042 Free Books & Documents. Review.
-
Erratum: High-Throughput Identification of Resistance to Pseudomonas syringae pv. Tomato in Tomato using Seedling Flood Assay.J Vis Exp. 2023 Oct 18;(200). doi: 10.3791/6576. J Vis Exp. 2023. PMID: 37851522
References
-
- Current Protocols in Immunology. Edited by: Coligan John E. (NIAID, NIH); Bierer Barbara (Brigham & Women’s Hospital); Margulies David H. (NIAID, NIH); Shevach Ethan M. (NIAID, NIH); Strober Warren (NIAID, NIH); Coico Richard (Weill Medical College of Cornell University); John Wiley & Sons, Inc., 2005.
-
- Standard practice for evaluation of immune responses in biocompatibility testing using ELISA tests, lymphocytes proliferation, and cell migration. ASTM F1906-98.
Publication types
LinkOut - more resources
Full Text Sources